Glycosmedia Weekly Diabetes News Update
View this email in your browser

Gold Sponsors:

Novo Nordisk

AstraZeneca

Boehringer Ingelheim

Silver Sponsors:

Abbott Diabetes Care

Ascensia Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 11/05/2021

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpE (Nature Medicine)


First ever injection pen recycling pilot launched in UK pharmacies

Novo Nordisk has launched the PenCycle scheme, enabling patients to recycle their FlexPen and FlexTouch devices by returning them to participating pharmacies or through pre-paid Royal Mail boxes (Pharmaceutical Journal)


Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study

URLi demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T2D  (Diabetes, Obesity and Metabolism)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2021 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp